February 13, 2020 / by HPSJ / Alerts, Pharmacy Announcements
Date: February 13, 2020 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update Business: Medi-Cal Effective 04/20/2020, the Pharmacy and Therapeutics Committee has approved the following changes: Additions to the Formulary: Phentermine (Adipex-P) 15mg, 30mg, 37.5mg capsule: No restrictions. Nateglinide […]
Read more
Formulary Update Effective 4/20/2020
February 13, 2020 / by HPSJ / Alerts, Pharmacy Announcements
Date: February 13, 2020 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update Business: Medi-Cal Effective 04/20/2020, the Pharmacy and Therapeutics Committee has approved the following changes: Additions to the Formulary: Phentermine (Adipex-P) 15mg, 30mg, 37.5mg capsule: No restrictions. Nateglinide […]
Read more
Improving the Quality of Care: Risks Associated with Use of Gabapentin
January 3, 2020 / by HPSJ / Pharmacy Announcements
Learning Objectives: Review the U.S. Food and Drug Administration (FDA) approved indications for gabapentinoids (gabapentin and pregabalin). Describe potential risks associated with combining gabapentin with opioids. Summarize best practices for responsible prescribing of gabapentin. Key Points: Recent restrictions on opioid prescribing have led clinicians to utilize alternative or complementary approaches to pain management, especially for […]
Read more
Formulary Update Effective February 24, 2020
December 12, 2019 / by HPSJ / Alerts, Pharmacy Announcements
Date: December 12, 2019 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update Effective February 24, 2020 Business: Medi-Cal Effective 02/24/2020, the Pharmacy and Therapeutics Committee has approved the following changes: Additions to the Formulary: Tranexamic Acid (Lysteda) 650 mg […]
Read more
Alert: New Global Guidelines for the Treatment of Asthma
November 13, 2019 / by HPSJ / Pharmacy Announcements
The World Health Organization (WHO) and the National Heart, Lung, and Blood Institute (NHLBI) established the Global Initiative for Asthma (GINA) in 1993 in order to increase awareness about asthma among health professionals, public health authorities, and the community, and to improve asthma prevention and management through a coordinated worldwide effort. The GINA Scientific Committee […]
Read more
2019 Immunization Updates: Flu, HepA, HPV, Measles, CA School Requirements
September 27, 2019 / by HPSJ / Pharmacy Announcements
Each year, the California Medi-Cal Drug Use Review (DUR) program issues an annual summary of updates on immunization guidelines, products, and/or research in collaboration with the California Department of Public Health (CDPH) Immunization Branch. For reference, the recommended immunization schedules for 2019 in the United States can be accessed on the Centers for Disease Control […]
Read more
Formulary Update – September 18, 2019
September 18, 2019 / by HPSJ / Alerts, Pharmacy Announcements
Date: September 18, 2019 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update – September 18, 2019 Business: Medi-Cal Managed Care Effective 12/02/2019, the Pharmacy and Therapeutics Committee has approved the following changes: Additions to the Formulary: Heparin sodium porcine/PF […]
Read more
Clinical Review Update: Concomitant Anticholinergic and Antipsychotic Use
September 12, 2019 / by HPSJ / Alerts, Pharmacy Announcements
Learning Objectives: Understand the role of anticholinergic medications in the prevention and treatment of antipsychotic-induced extrapyramidal symptoms (EPS). Describe factors that should be considered when deciding to initiate and/or continue the concomitant use of anticholinergic with antipsychotic medication therapy. Key Points: Anticholinergic medications, including benztropine and trihexyphenidyl, are often prescribed to prevent or treat antipsychotic-induced […]
Read more
Clinical Review Update: Morphine Equivalent Daily Dose
August 21, 2019 / by HPSJ / Pharmacy Announcements
Learning Objectives: Describe morphine equivalent daily dose (MEDD) and how it is being used to indicate potential dose-related risk for prescription opioid overdose. Summarize best practices for prescribing opioids. Identify resources available that promote responsible opioid prescribing, including online and mobile applications for calculation of morphine milligram equivalency. Describe recent legislation in California related to […]
Read more
Drug Safety Communication: Sleep Behavior Risks with Select Sleep Aids
July 17, 2019 / by HPSJ / Pharmacy Announcements
Eszopiclone, zaleplon, and zolpidem are sedative-hypnotic medications approved for the treatment of insomnia in adults who experience difficulty falling or staying asleep. On April 30, 2019, the U.S. Food and Drug Administration (FDA) announced they are requiring safety label changes for eszopiclone, zaleplon, and zolpidem because of the risk of complex sleep behaviors, including sleepwalking, […]
Read more
Formulary Update effective 8/19/2019
June 13, 2019 / by HPSJ / Alerts, Pharmacy Announcements
Date: June 12, 2019 To: Health Plan of San Joaquin (HPSJ) Practitioners, Providers and Facilities From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update effective 8/19/2019 Business: Medi-Cal Effective 8/19/2019, the Pharmacy and Therapeutics Committee has approved the following changes: Additions to the Formulary: Semaglutide (Ozempic) Pen Injector: PA required. […]
Read more